Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters











Database
Language
Publication year range
1.
J Affect Disord ; 219: 49-57, 2017 09.
Article in English | MEDLINE | ID: mdl-28521187

ABSTRACT

BACKGROUND: Depression is accompanied by activated neuro-oxidative and neuro-nitrosative pathways, while targeting these pathways has clinical efficacy in depression. This study aimed to investigate the effects of mirtazapine (MIRT) alone and combined with alpha-lipoic acid (ALA) against corticosterone (CORT) induced behavioral and oxidative alterations. METHODS: Male mice received vehicle or CORT 20mg/kg during 14 days. From the 15th to 21st days they were divided in groups administered: vehicle, MIRT 3mg/kg or the combinations MIRT+ALA100 or MIRT+ALA200. On the 21st day of treatment, the animals were subjected to behavioral tests. Twenty-four hours after the last drug administration hippocampus (HC) and striatum (ST) were dissected for the determination reduced glutathione (GSH), lipid peroxidation (LP) and nitrite levels. RESULTS: CORT induced anxiety- and depressive-like behaviors as observed by increased immobility time in the tail suspension test and decreased sucrose consumption. MIRT or MIRT+ALA are effective in reversing anxiety- and depressive-like behaviors induced by CORT. CORT and MIRT alone prolonged sleeping time and this effect was reversed by MIRT+ALA. CORT significantly increased LP, which was reversed by MIRT or MIRT+ALA. Nitrite levels were increased in CORT-treated animals and reversed by MIRT+ALA200 (HC), MIRT or MIRT+ALA (ST). LIMITATION: A relative small sample size and lack of a washout period between drug administration and behavioral testing. CONCLUSIONS: MIRT or MIRT+ALA reverse CORT-induced anxiety- and depressive-like behaviors probably via their central antioxidant effects. Augmentation of MIRT with ALA may reverse sedation, an important side effect of MIRT. Randomized controlled studies are needed to examine the clinical efficacy of this combination in human depression.


Subject(s)
Antidepressive Agents, Tricyclic/therapeutic use , Antioxidants/therapeutic use , Brain/drug effects , Depressive Disorder/drug therapy , Disease Models, Animal , Mianserin/analogs & derivatives , Thioctic Acid/therapeutic use , Animals , Brain/metabolism , Brain-Derived Neurotrophic Factor/metabolism , Corticosterone/toxicity , Depressive Disorder/chemically induced , Drug Combinations , Glutathione/metabolism , Hippocampus/metabolism , Lipid Peroxidation , Male , Mianserin/therapeutic use , Mice , Mirtazapine , Nitrites/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL